Abbott Laboratories (ABT) Cash from Financing Activities (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Cash from Financing Activities data on file, last reported at $17.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 942.48% year-over-year to $17.3 billion; the trailing twelve-month figure through Mar 2026 stood at $13.1 billion (up 307.85% YoY), and the FY2025 full-year result was -$6.3 billion, down 16.75% from the prior year.
• Cash from Financing Activities advanced to $17.3 billion in Q1 2026, from -$1.4 billion in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $17.3 billion in Q1 2026 to a low of -$3.8 billion in Q1 2022.
• A 5-year average of -$536.9 million and a median of -$1.5 billion in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities sank 295.35% in 2022 and soared 942.48% in 2026, its largest moves.
• Tracing ABT's Cash from Financing Activities over 5 years: stood at -$1.5 billion in 2022, then plunged by 40.84% to -$2.1 billion in 2023, then climbed by 9.31% to -$1.9 billion in 2024, then advanced by 24.93% to -$1.4 billion in 2025, then soared by 1339.3% to $17.3 billion in 2026.
• Business Quant data shows ABT's Cash from Financing Activities at $17.3 billion in Q1 2026, -$1.4 billion in Q4 2025, and -$1.8 billion in Q3 2025.